Celgene Cellular Therapeutics Company Profile

16:43 EDT 22nd September 2017 | BioPortfolio

Celgene International Sàrl, located in Boudry, in the Canton of Neuchâtel, Switzerland, is a wholly owned subsidiary and international headquarters of Celgene Corporation.

News Articles [2366 Associated News Articles listed on BioPortfolio]

Celgene exercises option to extend strategic collaboration scope and term with Forma Therapeutics

Forma Therapeutics and Celgene announced an innovative R&D partnership in 2014 to pursue ground-breaking medicines in oncology and other therapeutic areas.

Dragonfly Therapeutics and Celgene Collaborate on Novel NK Cell-Based Immunotherapies using Dragonfly’s TriNKET technology

CAMBRIDGE, Mass., June 12, 2017 /PRNewswire/ — Dragonfly Therapeutics, Inc. (“Dragonfly”), today announced a global strategic collaboration with Celgene Corporation and its affiliate...

Celgene, Dragonfly close $33M deal for blood cancer drug development

Celgene will pay Dragonfly Therapeutics $33 million as part of a deal that will allow Celgene to purchase and co-develop as m -More- 

Dragonfly and Celgene to Collaborate on Hematological Malignancies

NewsDragonfly Therapeutics announces strategic collaboration with Celgene to discover and develop novel Natural Killer (NK) cell-based immunotherapies using Dragonfly’s TriNKET technology platform.

Dragonfly, Celgene to collaborate on blood cancer therapy development

Dragonfly Therapeutics and Celgene will partner to cultivate new therapies for the treatment of hematologic cancers such as m -More- 

Dragonfly Therapeutics Announces Strategic Collaboration with Celgene to Discover and Develop Novel Natural Killer (NK) Cell-Based Immunotherapies using Dragonfly's TriNKET' technology platform

Dragonfly and Celgene enter into a five-year strategic collaboration. Celgene to receive exclusive options to license Dragonfly's product candidates focused on high-value targets in hematological ...

Dragonfly Therapeutics gibt strategische Zusammenarbeit mit Celgene zur Entdeckung und Entwicklung neuer Natural-Killer-Zellen (NK) basierter Immuntherapien bekannt, wobei die TriNKET-Technologieplattform von Dragonfly genutzt wird

Dragonfly und Celgene starten eine fünfjährige, strategische Zusammenarbeit. Celgene erhält exklusive Optionen zur Lizenzierung von Produktkandidaten von Dragonfly, welche auf entscheidene Punkte m...

Celgene options four immunotherapy candidates from Dragonfly

Celgene Corp. paid $33mm up front for an exclusive option to license global rights to up to four of Dragonfly Therapeutics Inc.’s immuno-oncology projects.

PubMed Articles [1924 Associated PubMed Articles listed on BioPortfolio]

Celgene eyes 'inverse vaccines' in Anokion and Delinia deals.

Cellular therapies in trauma and critical care medicine: Looking towards the future.

Shibani Pati and Todd Rasmussen summarize progress in preclinical research on cellular therapeutics for traumatic injury and its sequelae and discuss prospects for clinical translation.

Overcoming cellular barriers for RNA therapeutics.

RNA-based therapeutics, such as small-interfering (siRNAs), microRNAs (miRNAs), antisense oligonucleotides (ASOs), aptamers, synthetic mRNAs and CRISPR-Cas9, have great potential to target a large par...

Ultrastructural characterization of the Mitochondria-associated membranes abnormalities in human astrocytomas: Functional and therapeutics implications.

Mitochondria-associated membranes (MAMs) are currently considered an intracellular organelle "hot spot" for the intracellular signaling. MAMs are thought to function in cellular energy homeostasis, ap...

Targeting ligand-receptor interactions for development of cancer therapeutics.

The biological importance and druggable properties of receptors and their cognate ligands have designated them as especially useful clinical targets. This significance continues to expand as new molec...

Clinical Trials [695 Associated Clinical Trials listed on BioPortfolio]

Multi-center, Survival Data Collection in Subjects Previously Enrolled in Celgene Protocol CC-5013-MDS-003

Multi-center, survival data collection in subjects previously enrolled in Celgene Protocol CC-5013-MDS-003.

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Personalized Cellular Vaccine for Glioblastoma (PERCELLVAC)

Dendritic cell-based cellular vaccine for tumor therapy has shown efficacy. This study is designed to perform a personalized clinical trial by first analyzing the expression of tumor assoc...

Mitochondrial Bioenergetics and Role in Cellular Damage in Ischemic Myocardium

Cardiac ischemia is a common pathological condition, known to elicit multiple pathological processes at the cellular level. One of the most affected is thought to be cellular metabolism, k...

Companies [1463 Associated Companies listed on BioPortfolio]

Celgene Cellular Therapeutics

Celgene International Sàrl, located in Boudry, in the Canton of Neuchâtel, Switzerland, is a wholly owned subsidiary and international headquarters of Celgene Corporation. ...

Celgene International Sàrl

Celgene International Sàrl, located in Boudry, in the Canton of Neuchâtel, Switzerland, is a wholly owned subsidiary and international headquarters of Celgene Corporation. C...

Proteostasis Therapeutics, Inc.

Proteostasis Therapeutics (PTI) is developing novel disease-modifying therapeutics that target the cellular pathways regulating protein folding, trafficking, and clearance. The Pr...

PTC Therapeutics, Inc.

PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered small-molecule drugs that target post-transcriptional control processes. Post-tra...

Celgene Corporation

Celgene is a pharmaceutical company with a major focus on the discovery, development and commercialization of small molecules for cancer and immunological diseases.Celgene's medical research and devel...

More Information about "Celgene Cellular Therapeutics" on BioPortfolio

We have published hundreds of Celgene Cellular Therapeutics news stories on BioPortfolio along with dozens of Celgene Cellular Therapeutics Clinical Trials and PubMed Articles about Celgene Cellular Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Celgene Cellular Therapeutics Companies in our database. You can also find out about relevant Celgene Cellular Therapeutics Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks

Searches Linking to this Company Record